YY001 / Yuyao Biotech - LARVOL DELTA

An Phase I Study of YY001 in Patients with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Shanghai Yuyao Biotech Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Oncology • Solid Tumor

An open-label phase I study to evaluate the safety, tolerability and preliminary efficacy of YY001 in patients with advanced solid tumors. (ASCO 2024) - P1 | "The preliminary results suggest that YY001 had a manageable safety/tolerability profile and promising efficacy in patients with advanced solid tumors. YY001 will be combined with immune checkpoint inhibitor in a phase II study subsequently. Clinical trial information: NCT06228846."

Clinical • Metastases • P1 data • Gastroenterology • Gastrointestinal Disorder • Oncology • Solid Tumor

Remodeling the immune microenvironment for gastric cancer therapy through antagonism of prostaglandin E2 receptor 4. (PubMed, Genes Dis) - "Additionally, our research revealed that YY001 exhibited remarkable synergistic effects when combined with the PD-1 antibody and the clinically targeted drug apatinib, rather than fluorouracil. These findings suggest that YY001 holds great promise as a potential therapeutic strategy for gastric cancer, whether used as a standalone treatment or in combination with other drugs."

Journal • Gastric Cancer • Gastrointestinal Cancer • Immunology • Oncology • Solid Tumor

An Phase I Study of YY001 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Shanghai Yuyao Biotech Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor